Displaying 821 - 840 of 1605
Actavis, Inc. and Warner Chilcott PLC, In the Matter of
Under a settlement, the FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD).
FTC Announces Agenda for Workshop Examining Competition Issues Surrounding Biologic and Follow-on Biologic Medicines: Biosimilars and Interchangeables
FTC Staff Submits Comment to the Commission on Dental Accreditation Regarding its Proposed Standards for Dental Therapy Education Programs
FTC to Host Spring Seminars on Emerging Consumer Privacy Issues
Prepared Statement of the Federal Trade Commission On "Oversight of the Enforcement of the Antitrust Laws"
FTC Chairwoman Ramirez Testifies Before House Judiciary Subcommittee on Agency’s Enforcement of U.S. Antitrust Laws to Promote Competition and Protect Consumers
FTC to Host Workshop on the Competitive Impacts of State Regulations and Naming Conventions Concerning Follow-on Biologics
FTC Finalizes Amendments to the Premerger Notification Rules Related to the Transfer of Exclusive Patent Rights in the Pharmaceutical Industry
Economics at the FTC: Physician Acquisitions, Standard Essential Patents, and Accuracy of Credit Reporting
FTC Charges HCG Marketer with Deceptive Advertising
FTC Extends the Deadlines for Public Comments on 13 Matters Before the Agency
FTC Settles Charges That Actavis’s Proposed $8.5 Billion Acquisition of Warner Chilcott Would be Anticompetitive
Wellbutrin XL Antitrust Litigation, In re
FTC Puts Conditions on Mylan’s Proposed Acquisition of Agila from Strides
FTC Sends Refund Checks to Consumers Who Bought Walgreens' 'Wal-Born' Dietary Supplements
Consumer Protection and the Healthcare Marketplace
Displaying 821 - 840 of 1605